SEC Comment Letter 0000000000-23-008898 to LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Date: Aug. 15, 2023 · CIK: 0001335105 · Accession: 0000000000-23-008898
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273932
Letter
United States securities and exchange commission logo August 15, 2023 John Kovach Chief Executive Officer Lixte Biotechnology Holdings, Inc. 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 Re:Lixte Biotechnology Holdings, Inc. Registration Statement on Form S-3 Filed August 11, 2023 File No. 333-273932 Dear John Kovach: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David L. Ficksman, Esq.
Show Raw Text
United States securities and exchange commission logo
August 15, 2023
John Kovach
Chief Executive Officer
Lixte Biotechnology Holdings, Inc.
680 East Colorado Boulevard, Suite 180
Pasadena, California 91101
Re:Lixte Biotechnology Holdings, Inc.
Registration Statement on Form S-3
Filed August 11, 2023
File No. 333-273932
Dear John Kovach:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David L. Ficksman, Esq.